


PROGRAMME


26th International HIV Drug Resistance and Treatment Strategies Workshop programme – DAY 1 – Monday, 6 November 2017

Start time	Topic	Speaker
08:30:00 AM	Arrival and refreshments	
09:00:00 AM	Welcome and opening remarks	<i>Annemarie Wensing</i>
09:05:00 AM	Presentation: Why should drug resistance be prevented in clinical practice	<i>Deenan Pillay</i>
09:35:00 AM	Discussion	
09:45:00 AM	Presentation: HIV replication and selection of resistance: basic principles	<i>Douglas Richman</i>
10:15:00 AM	Discussion	
10:25:00 AM	Presentation: Mechanism of resistance	<i>Jonathan Schapiro</i>
10:55:00 AM	Discussion	
11:05:00 AM	Mid-morning break	
11:35:00 AM	Introduction of next presentation	<i>Annemarie Wensing</i>
11:40:00 AM	Presentation: Assessment of resistance	<i>Gillian Hunt</i>
12:00:00 PM	Presentation: Selection of resistance in clinical practice	<i>Carole Wallis</i>
12:20:00 PM	Discussion	
12:30:00 PM	Lunch	
01:30:00 PM	Presentation: Clinical management of drug resistance	<i>Annemarie Wensing</i>
01:50:00 PM	Discussion	
02:00:00 PM	Case studies	<i>Moherndran Archary, Richard Lessells and Sibusiso Kubheka</i>
03:30:00 PM	Afternoon refreshments	
04:00:00 PM	Presentation: Drug resistance as a public health threat	<i>Elliot Raizes</i>
04:20:00 PM	Discussion	
04:30:00 PM	Presentation: HIV latency	<i>John Mellors</i>
04:50:00 PM	Discussion	
05:00:00 PM	End	
05:30:00 PM	Welcome cocktail function	



PROGRAMME - continued

26 th International HIV Drug Resistance and Treatment Strategies Workshop programme – DAY 2- Tuesday, 7 November 2017			
Start time	Topic	Speaker	Abstract
08:30:00 AM	Arrival and refreshments		
09:00:00 AM	Welcome and opening remarks	<i>LOC</i>	
09:05:00 AM	Setting the scene: Overview of the resistance problem globally, reinforcing the need for the workshop	<i>Yunus Moosa</i>	
Pre-Treatment / Transmitted Drug Resistance		<i>Deenan Pillay and Doug Richman</i>	
09:25:00 AM	Plenary: Pre-treatment HIV drug resistance in LMIC	<i>Ravindra Gupta</i>	
09:45:00 AM	Source of HIV-1 drug-resistant minority variants in people who are recently infected	<i>Jean Mbisa</i>	1
09:55:00 AM	High levels of Pre-Treatment HIV Drug Resistance in South Africa, 2000 – 2016	<i>Benjamin Chimukangara</i>	2
10:05:00 AM	Sentinel Surveillance of HIV Drug Resistance among Patients Initiating Antiretroviral Treatment in South Africa	<i>Gillian Hunt</i>	3
10:15:00 AM	Plenary: Resistance from PrEP and microbicides?	<i>John Mellors</i>	
10:35:00 AM	High concentrations of long-acting rilpivirine (RPV LA) do not inhibit vaginal transmission of RPV-resistant HIV-1 nor select for high frequency drug resistance in humanized mice	<i>Zandrea Ambrose</i>	4
10:45:00 AM	The E138A Mutation Amplifies Resistance to Dapivirine in Combination with NNRTI Mutations	<i>Kerri Penrose</i>	5
10:55:00 AM	Discussion		
11:15:00 AM	Mid-morning break		
New Resistance Technologies		<i>Carole Wallis and Gillian Hunt</i>	
11:45:00 AM	Plenary: New technologies for drug resistance testing	<i>Roger Paredes</i>	
12:05:00 PM	PANDAA: A Novel, Scalable Genotyping Platform for Management of HIV Drug Resistance	<i>Iain Macleod</i>	18
12:15:00 PM	HIV DNA Genotyping by UDS compared with cumulative HIV RNA Genotypes in Pre-treated Patients	<i>Ali Si-Mohammed</i>	19
12:25:00 PM	PASeq.org: One-click, Cloud-based Web Service for NGS-based HIV genotyping Data Analysis	<i>Marc Noguera-Julian</i>	20
12:35:00 PM	Evaluation of low-cost “OLA-Simple” lab kit for detection of HIV drug resistance in dried blood spot specimens from South African infants	<i>Nuttada Panpradist</i>	21
12:45:00 PM	Discussion		
01:00:00 PM	Lunch		
02:00:00 PM	Poster Session	All	
03:00:00 PM	Afternoon break		
Children, Adolescents and Special Populations		<i>Elliot Raizes</i>	
03:30:00 PM	Plenary: HIV Drug Resistance in children and adolescents: Impact on treatment and outcomes	<i>Lee Fairlie</i>	
03:50:00 PM	HIV-1 viral infectivity and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study	<i>Jenny Coetzee</i>	30
04:00:00 PM	HIV-1 Treatment Failure and Extensive Drug Resistance in Perinatally-Infected Children Failing 1st-Line Antiretroviral Therapy in Western Kenya	<i>Rami Kantor</i>	31
04:10:00 PM	High levels of drug resistance among adolescents on first-line ART in Chiradzulu District, Malawi.	<i>Birgit Schramm</i>	32




PROGRAMME - continued

04:20:00 PM	A Public Sector Antiretroviral Treatment Programme for Treatment-Experienced Children and Adolescents in the Western Cape Province of South Africa Using Darunavir/Ritonavir-, Raltegravir- and Etravirine-Containing Regimens	<i>James Nuttall</i>	33
04:30:00 PM	Discussion		
04:50:00 PM	Closing remarks	<i>Douglas Richman</i>	
07:00:00 PM	Dinner at leisure		

26th International HIV Drug Resistance and Treatment Strategies Workshop programme – DAY 3 – Wednesday, 8 November 2017

Start time	Topic	Speaker	
08:30:00 AM	Arrival and refreshments		
09:00:00 AM	Welcome and opening remarks	<i>Deenan Pillay</i>	
Treatment Management		<i>Carole Wallis and Elliot Raizes</i>	
09:05:00 AM	Plenary: The challenges of treatment adherence in HIV infected adolescents	<i>Marnie Vujovic</i>	
09:25:00 AM	HIV drug resistance and tracing outcomes among antiretroviral therapy defaulters in Malawi	<i>Michael Jordan</i>	39
09:30:00 AM	Variation in Genotypic Resistance Patterns in HIV-1 Non-B Subtypes in Uganda and South Africa	<i>Suzanne McCluskey</i>	40
09:35:00 AM	Whole Genome Deep Sequencing of HIV Reveals Extensive Multi-class Resistance in Nigerian Patients Failing First-line Antiretroviral Therapy	<i>Kate El Bouzidi</i>	41
09:40:00 AM	Virologic failure, re-suppression and their determinants with Protease-Inhibitor-based Second line Antiretroviral Therapy in sub-Saharan Africa	<i>Andrea DeLuca</i>	42
09:45:00 AM	Drug level screening to determine eligibility for drug resistance testing in South African patients with virological failure of second-line ART using Dried Blood Spots	<i>Lucas Hermans</i>	43
09:50:00 AM	An Algorithm to Determine Appropriate Third-line Antiretroviral Regimens in Patients Failing Protease Inhibitor-based Regimens in Resource-limited Settings	<i>Michelle Moorhouse</i>	44
09:55:00 AM	HIV-1 drug resistance and third-line therapy outcomes in patients failing second-line therapy in Zimbabwe.	<i>Cleophas Chimbetete</i>	45
10:00:00 AM	HIV Multi-Drug Resistance is still a Clinical Relevant Issue Despite its Dramatic Drop over the Years	<i>Daniele Armenia</i>	46
10:05:00 AM	Keynote presentation: ARVs old and new – where do they fit	<i>Daniel Kuritzkes</i>	
10:35:00 AM	Discussion and questions		
11:00:00 AM	Mid-morning break		



PROGRAMME - continued

Resistance to Integrase Inhibitors and other new agents		<i>Annemarie Wensing and John Mellors</i>	
11:45:00 AM	Emergence of High Level Resistance to Dolutegravir with T97A Mutation in Integrase in Treatment Experienced Patients with Baseline Partial Sensitivity to Dolutegravir	<i>Jomy George</i>	55
11:55:00 AM	Case Report: Detection of Multi-Drug Resistant HIV-1 in a Patient on Integrase Inhibitor Based Antiretroviral Therapy in Botswana	<i>Seatla Kaelo</i>	56
12:05:00 PM	Primary Resistance to Integrase Strand Transfer Inhibitors in Patients Infected with Diverse HIV-1 Subtypes in Sub-Saharan Africa	<i>Seth Inzaule</i>	57
12:15:00 PM	Low Level Viremia during Dolutegravir-containing Regimens in two HIV-infected Patients	<i>Marije Hofstra</i>	58
12:25:00 AM	A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in Virologically-Suppressed HIV-1 Infected Adults Harboring the NRTI Resistance Mutation M184V and/or M184I (GS-US-292-1824)	<i>Ignacio Perez-Valero</i>	59
12:30:00 AM	Resistance Profile of HIV-1 Maturation Inhibitor GSK3532795	<i>Ira Dicker</i>	60
12:35:00 PM	Open discussion: Where are we with integrase inhibitors?		
01:00:00 PM	Lunch		
02:00:00 PM	Poster Session	All	
03:30:00 PM	Afternoon break		
Epidemiology of Resistance		<i>Gillian Hunt and Pontiano Kaleebu</i>	
04:00:00 PM	Modeling of Drug Resistance from Failure of WHO Recommended Preferred First-Line Antiretroviral Regimen for Adult HIV Infection in South Africa	<i>Ume Abbas</i>	62
04:10:00 PM	Trends of the Ongoing Spread of HIV Subtype A in Tel Aviv, Israel	<i>Dan Turner</i>	63
04:15:00 PM	HIV-1 CRF02_AG recombinant form genetically diverges over the years 2004-2016 and changes its pathogenic potential	<i>Claudia Alteri</i>	64
04:20:00 PM	Characterization of Subtype F HIV-1 Strains from Patients with Initial Poorer Treatment Response Compared to Individuals Infected with Subtype B HIV-1 Strains	<i>Samira Joussef</i>	65
04:25:00 PM	Trends of HIV-1 Drug Resistance During the Past 20 years of ARV Treatment in Uganda.	<i>Immaculate Nankya</i>	66
04:30:00 PM	Discussion and questions		
04:50:00 PM	Conference closing remarks	<i>John Mellors</i>	
07:00:00 PM	Workshop Awards Dinner		